메뉴 건너뛰기
International Journal of STD and AIDS
Volumn 16, Issue 2, 2005, Pages 139-141
The use of therapeutic drug monitoring in the management of protease inhibitor-related toxicity
Author keywords

Drug monitoring; Drug toxicity; Protease inhibitors
Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;
EID: 14644424605     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462053057602     Document Type: Review
Times cited : (9)
References (8)
  • 1
    • 0037192573 scopus 로고    scopus 로고
    • Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort
    • Dieleman JP, Jambroes M, Gyssens IC, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002;16:737-45
    • (2002) AIDS , vol.16 , pp. 737-745
    • Dieleman, J.P.1    Jambroes, M.2    Gyssens, I.C.3
  • 2
    • 79960445716 scopus 로고    scopus 로고
    • Adverse effects and drug interactions of medication commonly used in the treatment of adult HIV positive patients: Part 2
    • Heylen R, Miller R. Adverse effects and drug interactions of medication commonly used in the treatment of adult HIV positive patients: part 2. Genitourin Med 1997;73:5-11
    • (1997) Genitourin Med , vol.73 , pp. 5-11
    • Heylen, R.1    Miller, R.2
  • 3
    • 0032732512 scopus 로고    scopus 로고
    • The relationship between ritonavir plasma levels and side effects: Implications for therapeutic drug monitoring
    • Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side effects: implications for therapeutic drug monitoring. AIDS 1999;13:2083-9
    • (1999) AIDS , vol.13 , pp. 2083-2089
    • Gatti, G.1    Di Biagio, A.2    Casazza, R.3
  • 5
    • 0035202568 scopus 로고    scopus 로고
    • British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    • BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001;2:276-313
    • (2001) HIV Med , vol.2 , pp. 276-313
  • 6
    • 0037159936 scopus 로고    scopus 로고
    • Pharmadapt: A randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 Week results
    • Clevenbergh P, Garraffo R, Durant J, Dellamonica P. Pharmadapt: a randomized prospective study to evaluate the benefit of therapeutic drug monitoring of protease inhibitors: 12 week results. AIDS 2002;16:2311-15
    • (2002) AIDS , vol.16 , pp. 2311-2315
    • Clevenbergh, P.1    Garraffo, R.2    Durant, J.3    Dellamonica, P.4
  • 7
    • 0033545478 scopus 로고    scopus 로고
    • Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
    • Dieleman JP, Gyssens IC, van der Ende M, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999;13:473-8
    • (1999) AIDS , vol.13 , pp. 473-478
    • Dieleman, J.P.1    Gyssens, I.C.2    Van Der Ende, M.3    De Marie, S.4    Burger, D.M.5
  • 8
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-5
    • (2001) AIDS , vol.15 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3    Greub, G.4    Biollaz, J.5    Buclin, T.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.